Study Title
A Phase II Single Arm Trial Evaluating the Preliminary Efficacy of the Combination of 177Lu-DOTATATE and Nivolumab in Grade 3 Well-differentiated Neuroendocrine Tumours (NET) or Poorly Differentiated Neuroendocrine Carcinomas (NEC)
Study Details
Description:
This is a prospective, multi-centre, open-label, single-arm, stratified, exploratory, Phase 2 study evaluating the efficacy and safety of 177Lu-DOTATATE in combination with nivolumab in adult patients with Grade 3 neuroendocrine tumours (NET) or neuroendocrine carcinomas (NEC)
Sponsor:
Fundación de investigación HM
Contacts:
Antonio Cubillo, MDsecretaria@fundacionhm.com
+34 917567800
Government Study Link:
NCT04525638 - Click here to see study onClinicalTrials.gov